(Finance) – Arterra Biosciencea green biotech company specialized in research and development in the biotechnology sector and listed on Euronext Growth Milan, announced that the Production value recorded a decrease of 6.65% in 2023 compared to last year, going from 5.3 million to 5 million euros. This reduction, although a clear recovery compared to the values recorded in the first half of the year, must be entirely attributed to a contraction in sales of cosmetic raw materials in Asia, in particular towards the Chinese market, which went from 3 million to 2.6 million euros (- 10.23%). “The recovery that began in the third quarter of 2023 allows us to be optimistic about achieving next year’s objectives,” reads the note on the accounts.
The gross operating margin (EBITDA) achieved in 2023 was equal to approximately 1.6 million euros (EBITDA margin 32.15%), recording -25.37% compared to 2022. Net income of 2023 stands at approximately 1.1 million euros, equal to 21.74% of the value of production, a decrease compared to 2022 of 23.89%. There net financial position is positive (cash) for 5.7 million euros, compared to 5.5 million euros at 31 December 2022.
“The growth trend recorded by the sales of cosmetic raw materials in the last months of 2023 and those of the first months of 2024 allow us to be optimistic about achieving the objectives set for 2024”, commented theCEO Maria Gabriella Colucci.
The board of directors proposed a dividend of 0.1 euro per share, which will be paid on May 10, 2024, with ex-dividend date on May 8, 2024 and payment legitimation date (record date) on May 9, 2024.